These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28064209)

  • 41. Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials.
    Huang Y; Fan Y; Liu Y; Xie W; Zhang Z
    Clin Rheumatol; 2019 Oct; 38(10):2765-2776. PubMed ID: 31087226
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasmapheresis therapy in combination with TNF-α inhibitor and DMARDs: A multitarget method for the treatment of rheumatoid arthritis.
    Cheng Y; Yang F; Huang C; Huang J; Wang Q; Chen Y; Du Y; Zhao L; Gao M; Wang F
    Mod Rheumatol; 2017 Jul; 27(4):576-581. PubMed ID: 27830969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.
    Yellin M; Paliienko I; Balanescu A; Ter-Vartanian S; Tseluyko V; Xu LA; Tao X; Cardarelli PM; Leblanc H; Nichol G; Ancuta C; Chirieac R; Luo A
    Arthritis Rheum; 2012 Jun; 64(6):1730-9. PubMed ID: 22147649
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis.
    Iannone F; Lopalco G; Cantarini L; Galeazzi M; Lapadula G
    Clin Rheumatol; 2016 Jan; 35(1):19-23. PubMed ID: 26581205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort.
    Sugano E; Tanaka E; Inoue E; Sakai R; Abe M; Saka K; Sugitani N; Ochiai M; Yamaguchi R; Higuchi Y; Sugimoto N; Ikari K; Nakajima A; Yamanaka H; Harigai M
    Mod Rheumatol; 2022 Jul; 32(4):675-685. PubMed ID: 34918127
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to Young: A systematic review and meta-analysis.
    Dalal DS; Duran J; Brar T; Alqadi R; Halladay C; Lakhani A; Rudolph JL
    Semin Arthritis Rheum; 2019 Apr; 48(5):799-807. PubMed ID: 30185379
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries.
    Kilcher G; Hummel N; Didden EM; Egger M; Reichenbach S;
    Rheumatology (Oxford); 2018 Feb; 57(2):354-369. PubMed ID: 29149289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.
    Navarro-Millán I; Sattui SE; Curtis JR
    Clin Ther; 2013 Nov; 35(11):1850-61.e1. PubMed ID: 24156821
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors.
    Rendas-Baum R; Wallenstein GV; Koncz T; Kosinski M; Yang M; Bradley J; Zwillich SH
    Arthritis Res Ther; 2011 Feb; 13(1):R25. PubMed ID: 21324169
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece.
    Sidiropoulos P; Bounas A; Athanassiou P; Koutsianas C; Petrikkou E; Kaltsonoudis E; Drosos A; Vassilopoulos D
    Clin Rheumatol; 2020 Dec; 39(12):3643-3652. PubMed ID: 32458235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study.
    den Broeder AA; van Herwaarden N; van der Maas A; van den Hoogen FH; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    BMC Musculoskelet Disord; 2013 Oct; 14():299. PubMed ID: 24152421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis.
    Lloyd S; Bujkiewicz S; Wailoo AJ; Sutton AJ; Scott D
    Rheumatology (Oxford); 2010 Dec; 49(12):2313-21. PubMed ID: 20566736
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.
    Mok CC; Tsai WC; Chen DY; Wei JC
    Expert Opin Biol Ther; 2016; 16(2):201-11. PubMed ID: 26560845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature.
    Birnbaum H; Shi L; Pike C; Kaufman R; Sun P; Cifaldi M
    Expert Opin Pharmacother; 2009 Feb; 10(2):255-69. PubMed ID: 19236197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials.
    Law-Wan J; Sparfel MA; Derolez S; Azzopardi N; Goupille P; Detert J; Mulleman D; Bejan-Angoulvant T
    RMD Open; 2021 Nov; 7(3):. PubMed ID: 34789535
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Placebo and nocebo responses in randomized controlled trials of non-tumor necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumor necrosis factor inhibitors: A meta-analysis.
    Sung YK; Lee YH
    Z Rheumatol; 2023 Jan; 82(Suppl 1):59-67. PubMed ID: 34241691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. To switch or to change class-the biologic dilemma in rheumatoid arthritis.
    Villeneuve E; Haraoui B
    Nat Rev Rheumatol; 2010 May; 6(5):301-5. PubMed ID: 20386564
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents.
    Gülfe A; Aletaha D; Saxne T; Geborek P
    BMC Musculoskelet Disord; 2009 Apr; 10():41. PubMed ID: 19389230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.